Nektar Therapeutics (NKTR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$37.22-3.70%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Nektar Therapeutics’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	10.47M
EPS	—	-2.757
Annual ending 2026-12-31
Revenue	—	41.82M
EPS	—	-8.084
Annual ending 2027-12-31
Revenue	—	53.42M
EPS	—	-10.504

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital through stock offerings	The company focuses on its REZOLVE-AA study and managing capital through stock offerings.	Intact	No equity offerings or capital raises for 12 months	Equity Distribution Agreement active (May 2026) May 2026 EDA with Guggenheim/Wainwright for up to $150M; August 2026 news notes balance sheet under multi-year test. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive progress on REZOLVE-AA study	The company focuses on its REZOLVE-AA study and managing capital through stock offerings.	Under Pressure	New negative clinical trial results reported	Negative trial results reported Oct 2 downgrade cites REZPEG market outlook setback and clinical efficacy/safety concerns, confirming negative trial progress. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS loss narrows toward zero	A primary condition in Nektar Therapeutics's published investment case. The stated target is EPS loss less than -0.5 next quarter.	Broken	EPS loss worsens beyond -0.5 next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue decline moderates and stabilizes	A primary condition in Nektar Therapeutics's published investment case. The stated target is revenue decline better than -10% YoY.	Broken	revenue decline worsens beyond -10% YoY	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-10.50

$-11.87 → $-10.50 · observed estimates

FY2027 revenue$0.05B

$0.04B → $0.05B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-11.87	$36,987,460	5 / 11
2026-07-25	$-10.93	$36,906,208	7 / 9
2026-07-26	$-10.77	$36,987,462	7 / 9
2026-07-27	$-11.87	$36,987,460	5 / 11
2026-07-28	$-11.87	$36,987,460	5 / 11
2026-07-29	$-11.87	$36,987,460	5 / 11
2026-07-30	$-11.87	$36,987,460	5 / 11
2026-07-31	$-11.87	$36,987,460	5 / 11
2026-08-01	$-10.77	$36,987,462	8 / 9
2026-08-02	$-10.77	$36,987,462	8 / 9
2026-08-03	$-10.77	$36,987,462	8 / 9
2026-08-04	$-10.77	$36,987,462	8 / 9
2026-08-05	$-10.77	$36,987,462	8 / 9
2026-08-06	$-10.77	$36,987,462	8 / 9
2026-08-07	$-10.77	$36,987,462	8 / 9
2026-08-08	$-11.87	$36,987,460	5 / 11
2026-08-09	$-11.87	$36,987,460	5 / 11
2026-08-10	$-10.77	$36,987,462	8 / 9
2026-08-12	$-10.77	$36,987,462	8 / 9
2026-08-13	$-10.77	$36,987,462	8 / 9
2026-08-14	$-10.77	$36,987,462	8 / 9
2026-08-15	$-10.77	$36,987,462	8 / 9
2026-08-16	$-10.77	$36,987,462	8 / 9
2026-08-17	$-10.77	$36,987,462	8 / 9
2026-08-18	$-10.77	$36,987,462	8 / 9
2026-08-19	$-10.77	$36,987,462	8 / 9
2026-08-20	$-10.45	$58,544,903	7 / 9
2026-08-21	$-10.45	$58,541,266	7 / 9
2026-08-22	$-10.45	$58,541,266	7 / 9
2026-08-23	$-10.54	$56,996,161	8 / 10
2026-08-24	$-10.54	$56,996,161	8 / 10
2026-08-25	$-10.54	$56,996,161	8 / 10
2026-08-26	$-10.54	$56,996,161	8 / 10
2026-08-27	$-10.54	$56,996,161	8 / 10
2026-08-28	$-10.54	$56,996,161	8 / 10
2026-08-29	$-10.54	$56,996,161	8 / 10
2026-08-30	$-10.54	$56,996,161	8 / 10
2026-08-31	$-10.54	$56,996,161	8 / 10
2026-09-01	$-10.54	$56,996,161	8 / 10
2026-09-02	$-10.54	$56,996,161	8 / 10
2026-09-03	$-10.54	$56,996,161	8 / 10
2026-09-04	$-10.54	$56,996,161	8 / 10
2026-09-05	$-10.54	$56,996,161	8 / 10
2026-09-06	$-10.54	$56,996,161	8 / 10
2026-09-07	$-10.54	$56,996,161	8 / 10
2026-09-08	$-10.54	$56,996,161	8 / 10
2026-09-09	$-10.54	$56,996,161	8 / 10
2026-09-10	$-10.53	$56,996,161	8 / 10
2026-09-11	$-10.54	$56,996,161	8 / 10
2026-09-12	$-10.53	$56,996,161	8 / 10
2026-09-13	$-10.53	$56,996,161	8 / 10
2026-09-14	$-10.53	$56,996,161	8 / 10
2026-09-15	$-10.53	$56,996,161	8 / 10
2026-09-16	$-10.53	$56,996,161	8 / 10
2026-09-17	$-10.54	$56,996,161	8 / 10
2026-09-18	$-10.54	$56,996,161	8 / 10
2026-09-19	$-10.53	$56,996,161	8 / 10
2026-09-20	$-10.53	$56,996,161	8 / 10
2026-09-21	$-10.53	$56,996,161	8 / 10
2026-09-22	$-10.53	$56,996,161	8 / 10
2026-09-23	$-10.53	$56,996,161	8 / 10
2026-09-24	$-10.53	$56,996,161	8 / 10
2026-09-25	$-10.25	$56,996,161	8 / 10
2026-09-26	$-10.25	$56,993,103	8 / 10
2026-09-27	$-10.25	$56,993,103	8 / 10
2026-09-28	$-10.25	$56,993,103	8 / 10
2026-09-29	$-10.25	$56,993,103	8 / 10
2026-09-30	$-10.25	$56,993,103	8 / 10
2026-10-01	$-10.25	$56,996,436	11 / 10
2026-10-02	$-10.25	$56,996,436	11 / 10
2026-10-03	$-10.25	$56,996,436	11 / 10
2026-10-04	$-10.25	$56,996,436	11 / 10
2026-10-05	$-10.25	$56,996,436	11 / 10
2026-10-06	$-10.25	$56,996,436	11 / 10
2026-10-07	$-10.25	$56,996,436	11 / 10
2026-10-08	$-10.25	$56,996,436	11 / 10
2026-10-09	$-10.25	$56,996,436	11 / 10
2026-10-10	$-10.37	$55,991,710	11 / 11
2026-10-11	$-10.37	$55,991,710	11 / 11
2026-10-12	$-10.37	$55,991,710	11 / 11
2026-10-13	$-10.50	$53,419,482	12 / 11
2026-10-14	$-10.50	$53,419,482	13 / 13
2026-10-15	$-10.50	$53,419,482	13 / 13
2026-10-16	$-10.50	$53,419,482	13 / 13
2026-10-17	$-10.50	$53,419,482	13 / 13
2026-10-18	$-10.50	$53,419,482	13 / 13
2026-10-19	$-10.50	$53,419,482	13 / 13
2026-10-20	$-10.50	$53,419,482	13 / 13
2026-10-21	$-10.50	$53,419,482	13 / 13
2026-10-22	$-10.50	$53,419,482	13 / 13
2026-10-23	$-10.50	$53,419,482	13 / 13
2026-10-24	$-10.50	$53,419,482	13 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	9	1
2026-07-01	10	1
2026-08-01	10	2
2026-09-01	10	2
2026-10-01	11	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 12

$53.00New observation · no comparable prior

Leerink PartnersOct 12

$130.00New observation · no comparable prior

JefferiesOct 1

$150.00New observation · no comparable prior

$0$82.50$165.00

0 raises · 0 cuts · 0 unchanged · 3 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Positive progress on REZOLVE-AA studyPublished status: Under Pressure
EPS loss narrows toward zeroPublished status: Broken
Revenue decline moderates and stabilizesPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-64.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Nektar Therapeutics outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development story, not a profitable compounder: earnings quality is loss-making and recent financial performance is weak. The thesis is in a watch state, with management’s trial plans progressing but confidence now medium.

What's priced into Nektar Therapeutics

The valuation model indicates a 2.47-times premium versus peers, reflecting expectations of durable value, while the expectations gap is negative. That points to a demanding setup, but confidence in the valuation model is low and no fragility gates fired.

What the fundamentals likely do

Near term, results may remain uneven: the industry has a high miss rate, peers have missed lately, and the evidence flags a 40% miss probability for the next print. Over the multi-year view, management has started Phase 3 development plans for rezpegaldesleukin and has $1.02 billion in cash and investments at 2026-Q2, supporting development; reported alopecia areata results are encouraging but the evidence rates progress as mixed.

What Nektar Therapeutics hinges on

The central swing factor is whether rezpegaldesleukin shows consistent efficacy and safety as trials advance, including the planned alopecia areata program and later BLA submission. Near-term sector support also depends on bellwethers such as VRTX, REGN, and MRNA continuing to report strong results; weaker jobs data or weaker bellweller results could reduce that tailwind.